Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. The designation ...

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

U.S. stock futures declined on Thursday after ending higher on Wednesday. Futures of major benchmark indices were trading ...

Klotho Neurosciences, Inc. (KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it ...

NEW YORK, June 30, 2025 /CNW/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials ...

NEW YORK, June 30, 2025 /CNW/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials ...